Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2026)

Corcept Therapeutics has reported Long-Term Investments for 10 years, with the latest figure at $236.5 million in Q2 2026.

• Quarterly Long-Term Investments rose 36.85% year-over-year to $236.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $236.5 million (up 36.85% YoY) and the FY2025 annual result came in at $160.3 million, down 27.09% from the prior year.
• Long-Term Investments advanced to $236.5 million in Q2 2026 per CORT's latest filing, from $177.3 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $248.0 million in Q1 2025 and troughed at $4.9 million in Q3 2022.
• A 5-year average of $106.6 million and a median of $81.1 million in 2023 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments slumped 96.34% in 2022, then jumped 1118.0% in 2023.
• Over 5 years, Long-Term Investments stood at $4.9 million in 2022, then surged by 1055.77% to $57.2 million in 2023, then jumped by 284.48% to $219.8 million in 2024, then declined by 27.09% to $160.3 million in 2025, then jumped by 47.53% to $236.5 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $236.5 million, $177.3 million, and $160.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.